Yao, Y. et al. Efficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysis. Psychiatry Res. 335, 115886 (2024).
Romeo, B., Hermand, M., Pétillion, A., Karila, L. & Benyamina, A. Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: a systematic review. J. Psychiatr. Res. 137, 273–282 (2021).
Viljoen, G., Walter, H., Bendau, A., Koslowski, M. & Betzler, F. Predictors of therapeutic response to psychedelic-assisted therapy: a systematic review. J. Psychopharmacol. https://doi.org/10.1177/02698811251389581 (2025).
Haijen, E. C. H. M. et al. Predicting responses to psychedelics: a prospective study. Front. Pharmacol. 9, 897 (2018).
Johnson, M. W., Garcia-Romeu, A. & Griffiths, R. R. Long-term follow-up of psilocybin-facilitated smoking cessation. Am. J. Drug Alcohol Abuse 43, 55–60 (2017).
Roseman, L., Nutt, D. J. & Carhart-Harris, R. L. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front. Pharmacol. 8, 974 (2018).
Acevedo, E. C., Uhler, S., White, K. P. & Al-Shawaf, L. What predicts beneficial outcomes in psychedelic use? A quantitative content analysis of psychedelic health outcomes. J. Psychoactive Drugs 56, 1–10 (2024).
Smigielski, L., Scheidegger, M., Kometer, M. & Vollenweider, F. X. Psilocybin-assisted mindfulness training modulates self-consciousness AND brain default mode network connectivity with lasting effects. Neuroimage 196, 207–215 (2019).
Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235, 399–408 (2018).
Davis, A. K. et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78, 481 (2021).
Van Oorsouw, K., Toennes, S. W. & Ramaekers, J. G. Therapeutic effect of an ayahuasca analogue in clinically depressed patients: a longitudinal observational study. Psychopharmacology 239, 1839–1852 (2022).
Holze, F., Gasser, P., Müller, F., Dolder, P. C. & Liechti, M. E. Lysergic acid diethylamide–assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biol. Psychiatry 93, 215–223 (2023).
Bogenschutz, M. P. et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J. Psychopharmacol. 29, 289–299 (2015).
Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J. Psychopharmacol. 30, 1181–1197 (2016).
Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J. Psychopharmacol. 30, 1165–1180 (2016).
Agin-Liebes, G. et al. Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: an interpretive phenomenological analysis. Psychol. Addict. Behav. 38, 101–113 (2024).
Mian, M. N., Altman, B. R. & Earleywine, M. Ayahuasca’s antidepressant effects covary with behavioral activation as well as mindfulness. J. Psychoactive Drugs 52, 130–137 (2020).
Zeifman, R. J., Wagner, A. C., Monson, C. M. & Carhart-Harris, R. L. How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. J. Affect. Disord. 334, 100–112 (2023).
Davis, A. K., Xin, Y., Sepeda, N. & Averill, L. A. Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico. Am. J. Drug Alcohol Abuse 49, 587–596 (2023).
Sloshower, J. et al. Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial. Sci. Rep. 14, 8833 (2024).
Jungwirth, J., Von Rotz, R., Dziobek, I., Vollenweider, F. X. & Preller, K. H. Psilocybin increases emotional empathy in patients with major depression. Mol. Psychiatry 30, 2665–2672 (2025).
Dakwar, E. et al. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: results from a randomized, controlled laboratory study. Neuropharmacology 142, 270–276 (2018).
Romeo, B. et al. The intensity of the psychedelic experience is reliably associated with clinical improvements: a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 172, 106086 (2025).
Dahan, J. D. C., Dadiomov, D., Bostoen, T. & Dahan, A. Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome. npj Ment. Health Res. 3, 45 (2024).
Levin, A. W. et al. The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PLoS ONE 19, e0300501 (2024).
Liebnau, J., Betzler, F. & Kerber, A. Catalyst for change: psilocybin’s antidepressant mechanisms—a systematic review. J. Psychopharmacol. 39, 397–415 (2025).
Murphy, R. et al. Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. Front. Pharmacol. 12, 788155 (2022).
Koslowski, M., Johnson, M. W., Gründer, G. & Betzler, F. Novel treatment approaches for substance use disorders: therapeutic use of psychedelics and the role of psychotherapy. Curr. Addict. Rep. 9, 48–58 (2021).
Russ, S. L., Carhart-Harris, R. L., Maruyama, G. & Elliott, M. S. Replication and extension of a model predicting response to psilocybin. Psychopharmacology 236, 3221–3230 (2019).
Wolff, M. et al. Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance. Front. Psychiatry 11, 5 (2020).
Aday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. K. & Davoli, C. C. Predicting reactions to psychedelic drugs: a systematic review of states and traits related to acute drug effects. ACS Pharmacol. Transl. Sci. 4, 424–435 (2021).
Zhou, K. et al. Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use. PNAS Nexus 4, 560 (2025).
Ko, K., Carter, B., Cleare, A. & Rucker, J. Predicting the intensity of psychedelic-induced mystical and challenging experience in a healthy population: an exploratory post-hoc analysis. Neuropsychiatr. Dis. Treat. 19, 2105–2113 (2023).
Viljoen, G. & Betzler, F. Anxiety and affective symptoms related to the use of classic psychedelics: a systematic review. Curr. Top. Behav. Neurosci. 2024, 1–30 (2024).
Zilcha-Mano, S. et al. The relationship between alliance and outcome: analysis of a two-person perspective on alliance and session outcome. J. Consul. Clin. Psychol. 84, 484–496 (2016).
Marquett, R. M. et al. Psychosocial predictors of treatment response to cognitive-behavior therapy for late-life depression: an exploratory study. Aging Ment. Health 17, 830–838 (2013).
Solomonov, N. et al. Modifiable predictors of nonresponse to psychotherapies for late-life depression with executive dysfunction: a machine learning approach. Mol. Psychiatry 26, 5190–5198 (2021).
Bagby, R. M., Ryder, A. G. & Cristi, C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J. Psychiatry Neurosci. 27, 250–257 (2002).
Flückiger, C., Böhme, M., Schweizer, A.-M., Gómez Penedo, J.-M. & Wampold, B. E. In psychedelic-assisted therapy, the alliance in the psychotherapy component is as important as the drug. Psychother. Psychosom. 94, 304–305 (2025).
Thal, S., Engel, L. B. & Bright, S. J. Presence, trust, and empathy: preferred characteristics of psychedelic carers. J. Humanist. Psychol. https://doi.org/10.1177/00221678221081380 (2022).
Stauffer, C. S., Anderson, B. T., Ortigo, K. M. & Woolley, J. Psilocybin-assisted group therapy and attachment: observed reduction in attachment anxiety and influences of attachment insecurity on the psilocybin experience. ACS Pharmacol. Transl. Sci. 4, 526–532 (2021).
Wolff, M. et al. Common factors in altered states: understanding psychedelic therapy through the lens of Grawe’s general change mechanisms. Psychol. Rev. 132, 1467–1492 (2025).
Erritzoe, D. et al. Effects of psilocybin therapy on personality structure. Acta Psychiatr. Scand. 138, 368–378 (2018).
Barrett, F. S., Johnson, M. W. & Griffiths, R. R. Neuroticism is associated with challenging experiences with psilocybin mushrooms. Pers. Individ. Differ. 117, 155–160 (2017).
Holas, P. & Kamińska, J. Mindfulness meditation and psychedelics: potential synergies and commonalities. Pharmacol. Rep. 75, 1398–1409 (2023).
Lewis-Healey, E., Tagliazucchi, E., Canales-Johnson, A. & Bekinschtein, T. A. Breathwork-induced psychedelic experiences modulate neural dynamics. Cereb. Cortex https://doi.org/10.1093/cercor/bhae347 (2024).
Von Rotz, R. et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine 56, 101809 (2023).
Nygart, V. A. et al. Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. J. Psychopharmacol. 36, 932–942 (2022).
Low, Z. L. F. Intention-Setting among Recreational Psychedelic Users: Associated Acute Effects and Changes in Well-being. PhD thesis, Univ. at Albany, State Univ. of NY (2025); https://scholarsarchive.library.albany.edu/etd/134
Joyce, P. R. et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust. N. Z. J. Psychiatry 36, 384–391 (2002).
Garcia-Romeu, A. et al. Cessation and reduction in alcohol consumption and misuse after psychedelic use. J. Psychopharmacol. 33, 1088–1101 (2019).
Garcia-Romeu, A. et al. Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey. Front. Psychiatry 10, 955 (2020).
Xin, Y., Armstrong, S. B., Averill, L. A., Sepeda, N. & Davis, A. K. Predictors of psychedelic treatment outcomes among special operations forces veterans. Psychol. Conscious. https://doi.org/10.1037/cns0000374 (2023).
Beard, J. I. L. & Delgadillo, J. Early response to psychological therapy as a predictor of depression and anxiety treatment outcomes: a systematic review and meta-analysis. Depress. Anxiety 36, 866–878 (2019).
Nordmo, M., Monsen, J. T., Høglend, P. A. & Solbakken, O. A. Investigating the dose–response effect in open-ended psychotherapy. Psychother. Res. 31, 859–869 (2021).
Rost, F. et al. The complexity of treatment-resistant depression: a data-driven approach. J. Affect. Disord. 358, 292–301 (2024).
Foltin, R. W., Luba, R., Chen, Y., Wang, Y. & Evans, S. M. Impulsivity in cocaine users compared to matched controls: effects of sex and preferred route of cocaine use. Drug Alcohol Depend. 226, 108840 (2021).
Stellern, J. et al. Emotion regulation in substance use disorders: a systematic review and meta-analysis. Addiction 118, 30–47 (2023).
Johnson, M. W. Consciousness, religion, and gurus: pitfalls of psychedelic medicine. ACS Pharmacol. Transl. Sci. 4, 578–581 (2021).
Mion, G. & Villevieille, T. Ketamine pharmacology: an update. CNS Neurosci. Ther. 19, 370–380 (2013).
Mathai, D. S., Meyer, M. J., Storch, E. A. & Kosten, T. R. The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: a systematic review. J. Affect. Disord. 264, 123–129 (2020).
Machado-Vieira, R., Salvadore, G., DiazGranados, N. & Zarate, C. A. Jr. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol. Ther. 123, 143–150 (2009).
Passie, T., Seifert, J., Schneider, U. & Emrich, H. M. The pharmacology of psilocybin. Addict. Biol. 7, 357–364 (2002).
Holze, F., Becker, A. M., Kolaczynska, K. E., Duthaler, U. & Liechti, M. E. Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants. Clin. Pharmacol. Ther. 113, 822–831 (2023).
Studerus, E., Kometer, M., Hasler, F. & Vollenweider, F. X. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J. Psychopharmacol. 25, 1434–1452 (2011).
Mertens, L. J. et al. Methodological challenges in psychedelic drug trials: efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE)—rationale and study design. Neurosci. Appl. 1, 100104 (2022).
Aday, J. S. et al. Personal psychedelic use is common among a sample of psychedelic therapists: implications for research and practice. Psychedelic Med. 1, 27–37 (2023).
Braun, V. & Clarke, V. Using thematic analysis in psychology. Qual. Res. Psychol. 3, 77–101 (2006).
Viljoen, G. et al. Predictors of psychedelic-assisted therapy response (PREPARE-study): the therapist’s perspective. figshare https://doi.org/10.6084/m9.figshare.30218056 (2026).
Leave a Reply